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between beneficial and harmful cytokines or whether 
some cytokines are beneficial in low amounts but toxic at 
high levels. Studies addressing these types of questions 
will provide new insights into the liver injury and clinical 
manifestations of alcoholic hepatitis. 
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PREDICTING DRUG INTERACTIONS USING 
CULTURED HUMAN HEPATOCYTES 
Pichard L, Fabre I ,  Fabre G, Domergue J,  Saint Aubert 
B, Mourad G, Maurel P. Cyclosporin A drug interac- 
tions: screening for inducers and inhibitors of cy- 
tochrome P-450 (cyclosporin A oxidase) in primary 
cultures of human hepatocytes and in liver microsomes. 
Drug Metab Dispos 1990;18:595-606. 
ABSTRACT 
In previous papers we demonstrated that cyclo- 
sporin A (CsA) was specifically oxidized in rabbit and 
human liver by cytochrome P-45OIIIA. We therefore 
anticipated that any drug that is an inducer or an 
inhibitor of this cytochrome should lead to interaction 
with CsA when given in association with it. In order to 
confirm this hypothesis, primary cultures of human 
hepatocytes and human liver microsomes were used to 
“reproduce” in uitro clinically significant interactions 
observed between CsA and drugs known either as 
specific inducers (i.e., rifampicin) or as specific inhib- 
itors (i.e., erythromycin) of P-45OIIIA. Our results were 
in close agreement with the clinical reports. Human 
hepatocytes maintained in primary cultures for 72 hr 
in the presence of 50 p M  rifampicin exhibited in- 
creased levels of P-450IIIA, determined by Western blot 
using specific antibodies, and concomitant increase 
in CsA oxidase activity, determined by HPLC anal- 
ysis of extra and intracellular media. Conversely, 
these cultures exhibited erythromycin concentration- 
dependent decreases in CsA oxidase activity when 
incubated in the presence of 5,20, and 100 p M  eryth- 
romycin. In addition, a Lineweaver-Burk analysis of 
the erythromycin-mediated inhibition of CsA oxidase 
activity in human liver microsomes revealed compet- 
itive inhibition (with Ki of 75 pM) as expected, this 
macrolide being a specific substrate of P-45OIIIA. Using 
this experimental approach, 59 molecules represen- 
tative of 17 different therapeutic classes were screened 
for inducers and inhibitors of CsA oxidase activity. Our 
results allowed us to elucidate the molecular mech- 
anism of previously observed, but unexplained, drug 
interactions involving CsA, and to detect drugs that 
should interfere with CsA metabolism as inducers or 
inhibitors. Drugs detected as potential inducers of CsA 
oxidase included rifampicin, sulfadimidine, phenobar- 
bital, phenytoin, phenylbutazone, dexamethasone, 
sulfinpyrazone, and carbamazepine. Drugs detected 
as potential competitive inhibitors included tri- 
acetyloleandomycin, erythromycin, josamycin, mide- 
camycin, ketoconazole, miconazole, midazolam, nife- 
dipin, diltiazem, verapamil, nicardipine, ergotamine, 
dihydroergotamine, glibenclamide, bromocryptine, 
ethynylestradiol, progesterone, cortisol, prednisone, 
prednisolone, and methylprednisolone. Finally cefo- 
perazone, cefotaxime, ceftazidime, isoniazide, doxycy- 
cline, spiramycin, sulfamethoxazole, norfloxacin, pe- 
floxacin, vancocin, trimethoprime, amphotericine B, 
valproic acid, quinidine, cimetidine, ranitidine, ome- 
prazole, diclofenac, aspirin, paracetamol, debriso- 
quine, guanoxan, captopril, furosemide, acetazol- 
amide, sparteine, gliclazide, and imipramine were 
found not to interfere with the hepatic metabolism of 
CsA. 
COMMENTS 
More than 100 different cytochromes P450 (P450s) 
have been identified in laboratory animals, and at least 
20 have been identified in man (1). The P450s that 
appear to be most involved in drug metabolism belong to 
three distinct families (designated as I, I1 and III), which 
are further divided into subfamilies (designated by 
capital letters). A variety of techniques have been used 
to determine which P450s metabolize which drugs. The 
newest technique is the insertion of specific P450 cDNAs 
into cell lines that are deficient in drug-metabolizing 
capability. Such cell lines, some of which are now 
commercially available, then produce functional en- 
zymes and can therefore be used to characterize the 
catalytic properties of individual P450s. This technique 
has been used to show that two closely related enzymes 
within the P450IIIA subfamily are capable of generating 
the major metabolites of cyclosporin A (CsA) produced in 
patients in viuo (2). P450IIIA catalytic activity varies at 
least 10-fold and appears to have a unimodal distri- 
bution among patients (i.e., discrete “rapid” and “poor” 
metabolizer populations have not been identified) (1). 
Enzymes outside the P4501IIA subfamily probably 
contribute little to CsA metabolism because antibodies 
that selectively recognize P450IIIA enzymes inhibit 
most of the CsA metabolism that occurs in human liver 
microsomes (3-5). 
In a recent study ( 6 )  where P4501IIA activity was 
noninvasively measured in 32 patients before they began 
treatment with CsA, patients with higher P450IIIA 
activity had lower dose-adjusted blood levels of CsA, and 
patients with low P450IIIA activity had higher dose- 
adjusted blood levels. This inverse correlation was 
highly significant and suggests t,hat the catalytic activity 
of P450III.A is rate limiting in the metabolism of CsA. It 
logically follows that any drug that influences the 
catalytic activity of P450IIIA could produce an inter- 
action with CsA. If a drug is normally metabolized by 
P450IIIA and therefore competes with CsA for binding 
to the substrate binding (active) site of the enzyme, the 
rate of CsA metabolism should fall. Conversely, 
treatment with some drugs could result in the induction 
of P450IIIA catalytic activity, which could result in 
accelerated metabolism of CsA. 
Pichard et al. directly investigated the role of 
P450IIIA in drug interactions by measuring CsA me- 
tabolism in cultured human hepatocytes exposed to a 
battery of medications. When drugs previously reported 
to cause clinically significant elevations in CsA blood 
levels were added to the culture medium, the result 
was a diminished rate of CsA metabolism. The inves- 
tigators then characterized the interactions between 
these drugs and P450IILA in human liver microsomes. 
In most cases, they found that the inhibition of 
CsA metabolism in the hepatocytes resulted from 
competitive inhibition of P450IIIA catalytic activity. 
most likely because the inhibiting drugs were also 
metabolized by P450IIIA. When drugs known to 
produce clinically significant decreases in CsA blood 
levels were added to the culture medium, accelerated 
metabolism of CsA was observed. This induction was 
accompanied by increases in the hepatocyte concen- 
tration of P450IIIA protein. These data strongly 
support the idea that most drug interactions involv- 
ing CsA result from competitive inhibition or induction 
of P450IIIA. 
It should be pointed out that the data presented are 
not entirely consistent with a primary role of liver 
P450IIIA in drug interactions. For example, the K,  
determined for erythromycin inhibition of CsA metab- 
olism in human liver microsomes was 75 F-moliL, a 
concentration that exceeds by at least an order of 
magnitude the peak blood levels observed in patients 
treated with erythromycin. Indeed, intravenous admin- 
istration of erythromycin has been reported to have 
relatively small effects on the pharmacokmetics of CsA 
(7). It may therefore be important that P450IIIA 
enzymes are also abundant in jejunal enterocytes where 
they may significantly contribute to “first pass’’ metab- 
olism of CsA (8). After oral dosing. the enterocyte 
concentrations of erythromycin could well exceed the 
determined K,, resulting in significant inhibition in gut 
metabolism of CsA. 
The data presented by Pichard et al. add to the 
growing body of literature supporting cultured human 
hepatocytes as a valid model for studying the regulation 
of human liver P450s. In this regard, human hepato- 
cytes appear to be “hardier” than rat hepatocytes in that 
the latter tend to rapidly lose responsiveness to many 
inducers in culture. The importance of the work by 
Pichard et al. is that it provides the best evidence to date 
that in vitro models of P450 regulation are capable of 
yielding new and important information for clinicians. 
For example, the investigators were able to identify 
some drugs that are potent inhibitors of P450IIIA (such 
as miconazole) or inducers of P450IIIA (sulfinpyrazone 
and phenylbutazone) that have not been previously 
reported to interact with CsA. It seems reasonable to 
alert physicians to these likely interactions. Pichard et 
al. were also able to identify many drugs that appeared 
to have no effect on P450IIIA activity and that may 
therefore be safe alternatives to drugs that interact with 
CsA. For example, they suggested that the macrolide 
antibiotic spiramycin, which had no effect on CsA 
metabolism, would be a suitable substitute for erythro- 
mycin in patients receiving CsA. Finally, although the 
investigators focused on CsA, their data provide po- 
tential explanations for some well-known interactions 
involving other drugs. Any drug shown to be a substrate 
for P450IIIA should be metabolized at a reduced rate in 
the presence of a P450IIIA inhibitor and at  an increased 
rate in the presence of a P450IIIA inducer. For example, 
prednisone and troleandomycin (TAO) were shown to 
inhibit CsA metabolism and to bind to P450IIIA. It 
therefore seems likely that the “steroid sparing” effect 
of TAO in patients with chronic obstructive pulmonary 
disease is caused by reduced metabolism of prednisone 
by P450IIIA resulting from the inhibition of the enzyme 
by TAO. Conversely, because at least some estrogens are 
metabolized by P450IIIA (9), induction of P450IIIA by 
rifampicin may explain why women treated with this 
drug may experience failure of oral contraceptives 1). 
It remains to be determined how often the activity of 
a P450 is rate limiting in the metabolism and elimi- 
nation of drugs. Nonetheless, the concepts raised by this 
article have not escaped the notice of drug companies 
who would obviously like to be alerted to potential drug 
interactions before they are experienced in clinical trials. 
Many companies are setting up human hepatocyte 
culture facilities, although it is likely that difficulty 
obtaining human liver tissue will limit some of the 
potential applications. Fortunately, Pichard et al. found 
that the inhibition of CsA metabolism in hepatocytes 
could be reproduced in microsomes in most cases. It 
should therefore be possible to use recombinant P450s 
andlor human liver microsomes to identify most drugs 
likely to produce interactions by inhibiting P450s. 
Induction studies, on the other hand, currently require 
living cells. Unfortunately, animal-model results often 
cannot be extrapolated to humans because interspecies 
EDITORS ABSTRACT differences exist in the regulation of at  least some of the 
P450s (10). As the molecular mechanisms that underlie 
induction of human liver P45Os are characterized, it is 
likely that cell-free assays will be developed to screen 
drugs for induction properties. 
These two reports describe recombinant DNA tests 
that can identify individuals having a defect in the 
cflochrome P450IID6 (CYP2DGkmediated oxidative 
metabolism of debrisoquine and more than two dozen 
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metaboliz& (PM), representiig 5% to 10% o< the 
northern European white population is homozygous 
for an autosomal recessive trait. Compared with the 
extensive metabolizer (EM) phenotype, the PM indi- 
vidual is more prone to toxicity caused by some of these 
drugs. Curiously, the PM phenotype appears to be 
associated with a lower risk of lung and bladder cancer. 
Gough and coworkers propose that the primary gene 
defect associated with the CYP2D6 polymorphism ap- 
pears to be a G to A transition mutation affecting the 
splice junction of intron 3Iexon 4 of the CYP2D6 gene. 
They offer a polymerase chain reaction (PCR) ampli- 
fication method for diagnosing three variant alleles 
and claim to have predicted the phenotype of all 
normal and 34 of 42 (81%) PM individuals. Based on the 
known frequencies of those variant alleles detectable 
by this method, however, the assay would be expected 
to predict less than 60% of PM patients. Heim and 
Meyer, on the other hand, have combined allele- 
specific PCR with restriction fragment length polymor- 
phism (RFLP) patterns to identify more than 95% of all 
mutant alleles, suggesting that their assay would accu- 
rately predict more than 90% of all P M  individuals. 
Using this latter assay or a similar test with further 
improvements, especially in combination with family 
studies, it should soon be possible for the physician to 
determine the CYP2D6 phenotype of the patient, 
thereby avoiding toxic drug overdoses. 
COMMENTS 
To appreciate these two recent papers, this com- 
mentary briefly reviews our current understanding of 
pharmacogenetics and drug metabolism, what the de- 
brisoquine polymorphism represents and how pharma- 
cogenetic disorders could lead to differences in indi- 
vidual risk of toxicity. Also, it is interesting to consider 
why striking ethnic differences in drug metabolism 
might exist in the first place. 
Pharmacogenetics is defined as the study of inherited 
traits that are responsible for unusual drug responses ( 1, 
2). These responses can be immediate (e.g., hypotension, 
rash), subacute (e.g., peripheral neuropathy, lupoid 
hepatitis) or delayed (e.g., cancer). Many idiosyncratic 
responses reflect underlying differences, ranging from 
10-fold to more than 200-fold, in the expression of 
IDENTIFICATION OF GENETIC DIFFERENCES IN genes-encoding, drug-metabolizing enzymes. In the 
medical field it is important to recognize that subpopu- 
lations exist with substantially increased risk of cancer 
DRUG METABOLISM: PREDICTION OF 
INDIVIDUAL RISK OF TOXICITY OR CANCER 
or toxicity caused by prescribed medications, exposures 
to chemicals in the workplace and in the diet and other 
pollutants in the environment. prediction of individual 
tively simple and unequivocal tests. As has already been 
A C ~  J s j  ‘purr NK, Moss JE, Gaedigk 
Eichelbaum M ,  wolf CR. Identification of the Primary 
1990;347:773-776. 
gene defect at the cYtochrome p , ~ ~ ~  cyp2D locus. Nature risk will require the development of inexpensive, rela- 
Heim M,  Meyer UA. Genotyping of poor metabolisers of found with many “inborn errors of metabolism,” the 
debrisoquine by allele-specific PCR amplification. development of a predictive test for detecting genetic 
Lancet 1990;336:529-532. variants is not always straightforward because of the 
